Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Basal Cell 3Pancreatic Neoplasms 2Neoplasms 2Basal Cell Nevus Syndrome 2Head and Neck Neoplasms 1Chondrosarcoma 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

tazarotene 2gusacitinib 2Photochemotherapy 2IPI-926 2HhAntag691 2Drug Evaluation 2Aminolevulinic Acid 21-phenyl-3,3-dimethyltriazene 2sonidegib 1merphos 1Vincristine 1Solutions 1Sirolimus 1Red Light 1Microarray Analysis 1Methotrexate 1Mental Status and Dementia Tests 1Mass Spectrometry 1Gene Expression Profiling 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Comparative Genomic Hybridization 1Carnitine 1Carboplatin 1Blue Light 1Biopsy 1BMS-833923 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Basal Cell Nevus Syndrome × IPI-926 × Clear all
NCT02762084 2020-07-23

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PellePharm, Inc.

Phase 2 Completed
17 enrolled 22 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT02828111 2019-01-08

BCC

PellePharm, Inc.

Phase 2 Completed
36 enrolled 17 charts
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡